BlackThorn Therapeutics Secures $40M Series A Funding
Summary
BlackThorn Therapeutics, a South San Francisco, CA-based clinical stage biopharmaceutical company discovering and developing targeted treatments for neurobehavioral disorders, closed a $40m Series A financing.Led by Mark Corrigan, M.D., executive chairman, BlackThorn is building a pipeline of treatments through its INFORM™ platform, which links brain physiology and its relationship to behavior.The lead program will evaluate BTRX-246040, an antagonist of the nociceptin receptor (NOPR), a target linked to multiple neurobehavioral disorders, which is currently entering phase 2 clinical trials.The scientific advisory board is led by co-chairs Steven Hyman, M.D., director of the Stanley Center for Psychiatric Research and core member at the Broad Institute of MIT and Harvard University, and Matt State, M.D., Ph.D., chair of the UCSF Department of Psychiatry and director of the Langley Porter Psychiatric Institute.In addition, Thomas Daniel, M.D., most recently president of research and early development at Celgene Corporation, serves as a senior advisor to the team.